Angiogenesis Inhibitors
Learn MoreOur Ubiquitin Activating Enzyme E1 Inhibitor is a cutting-edge biological product that has the potential to revolutionize the field of protein degradation Ubiquitin activating enzymes play a crucial role in the ubiquitin-proteasome system which is responsible for selective protein degradation within cells By inhibiting the activity of these enzymes our product offers researchers a powerful tool to explore the intricate mechanisms of protein turnover and opens up new avenues for therapeutic interventions With its advanced design and proven efficacy our Ubiquitin Activating Enzyme E1 Inhibitor is an essential asset for the study of protein degradation pathways and the development of novel therapeutic strategies
Catalog Number | Chemical Name | CAS # | Price |
---|---|---|---|
EI-1834 | PYR-41 | 418805-02-4 | Online Inquiry |
The Ubiquitin Activating Enzyme E1 Inhibitor has a broad range of applications in biological research and therapeutic development In the field of research this inhibitor is commonly used to study the role of ubiquitin activation in various cellular processes By inhibiting the activity of the E1 enzyme scientists can gain insights into the functions of ubiquitin in protein degradation DNA repair and cell signaling pathways
In terms of therapeutic applications the Ubiquitin Activating Enzyme E1 Inhibitor shows promising potential in the treatment of certain diseases Ubiquitin-mediated proteolysis plays a crucial role in regulating protein levels and maintaining cellular homeostasis Dysregulation of this process has been implicated in various disorders including cancer neurodegenerative diseases and autoimmune conditions By inhibiting the E1 enzyme this inhibitor offers a targeted approach to modulating ubiquitin signaling and potentially addressing the underlying mechanisms of these diseases
Furthermore the Ubiquitin Activating Enzyme E1 Inhibitor holds potential in combination therapies with existing treatments By sensitizing cancer cells to chemotherapy or enhancing the efficacy of immunotherapies this inhibitor may improve the outcomes of cancer patients Additionally the ability to selectively inhibit the E1 enzyme opens up possibilities for developing personalized treatments based on the specific molecular characteristics of each patient's disease
Overall the Ubiquitin Activating Enzyme E1 Inhibitor is a valuable tool in biological research and offers promising therapeutic potential for various diseases Its precise and targeted mechanism of action makes it an exciting area of study for scientists and a potential game-changer in the field of medicine
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.